Dr Ravi Krishnan (CSO):
"Furthermore, the observation that PPS appears to have durable biological activity for an animal study, extending into the post-acute phase of
the response to regress the progression of pulmonary fibrosis in the lung is compelling. These findings may have potential implications in halting the progression towards chronic lung disease by early intervention with PPS at the onset of acute lung inflammation where there is a significant unmet medical need."
Ann: POSITIVE TOP-LINE RESULTS FROM PRECLINICAL STUDY IN ARDS, page-8
-
- There are more pages in this discussion • 73 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $92.81M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 29.0¢ | 25.5¢ | $430.3K | 1.585M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5500 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.5¢ | 36162 | 3 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |